Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for REBINYN (Coagulation Factor IX (Recombinant), GlycoPEGylated) for the treatment of adults and children with hemophilia B.
Hemophilia B is a chronic and inherited bleeding disorder that affects approximately 5,000 people in the U.S. People with hemophilia B have deficient blood clotting factor IX activity that results in prolonged or spontaneous bleeding, especially into the muscles, joints or internal organs.
REBINYN is the brand name for nonacog beta pegol, N9-GP. REBINYN is indicated for on-demand treatment and control of bleeding episodes, and the perioperative management of bleeding in adults and children with hemophilia B. REBINYN is not indicated for routine prophylaxis or for immune tolerance induction in patients with hemophilia B. The efficacy and safety evaluation was based on 115 patients across the four paradigm clinical trials, and the approval follows the Blood Products Advisory Committee meeting held on April 4, 2017.
“We would like to thank the patients who participated in the clinical studies that led to this decision. Thanks to their commitment, we are able to continue to provide new medicines for people with hemophilia,” said Bill Breitenbach, Vice President, Biopharmaceuticals Portfolio, Novo Nordisk. “We are committed to the hemophilia community and will continue on our path to bring this new extended half-life treatment to patients who need it.”
Novo Nordisk expects to launch REBINYN in the U.S. in the first half of 2018.
Filed Under: Drug Discovery
